Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Current Opinion in Urology|December 4, 2012
Hormonal manipulation of benign prostatic hyperplasiaFerenc G Rick, Seyed H Saadat, Luca Szalontay, et al.
Peptides|July 17, 2010
A correlation of endocrine and anticancer effects of some antagonists of GHRHMagdolna Kovács, Andrew V Schally, Florian Hohla, et al.
The Prostate|October 15, 2010
LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasiaFerenc G Rick, Andrew V Schally, Norman L Block, et al.
Oncotarget|June 8, 2013
Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108Karoly Szepeshazi, Andrew V Schally, Norman L Block, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 16, 2011
Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasiaFerenc G Rick, Andrew V Schally, Norman L Block, et al.
The Prostate|August 30, 2008
Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138Elmar Heinrich, Andrew V Schally, Stefan Buchholz, et al.
Oncotarget|July 25, 2012
Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]Karoly Szepeshazi, Andrew V Schally, Gunhild Keller, et al.
The Journal of Urology|February 21, 2012
Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkageFerenc G Rick, Luca Szalontay, Andrew V Schally, et al.
Cell Cycle (Georgetown, Tex.)|October 26, 2012
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancerFerenc G Rick, Stephan Seitz, Andrew V Schally, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2014
Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancerCale D Fahrenholtz, Ferenc G Rick, Maria I Garcia, et al.
Pageof 6